Patient considerations in frontline treatment selection for renal cell carcinoma

Bradley McGregor, MD, explains patient considerations that come into play now that there are several promising treatment options, such as dual immunotherapy combos and immunotherapy/TKI combos, in the frontline setting for the treatment of patients with renal cell carcinoma. McGregor is clinical director, Lank Center for Genitourinary Oncology, senior physician, instructor in Medicine, Harvard Medical School, Dana-Farber Cancer Institute.